Cancer chemotherapy--ribonucleases to the rescue
Related Experiment Video
Updated: Oct 7, 2026
08:32
Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
Published on: May 23, 2025
1Department of Biochemistry, University of Wisconsin-Madison, 53706, USA.
Chemistry & Biology
|May 19, 2001
Abstract:
Ribonucleases, once dismissed as uninteresting digestive enzymes, have been shown to have remarkable biological activities. Onconase, from the Northern leopard frog, is currently in clinical trials as a cancer chemotherapeutic. Recent research has revealed some key factors responsible for the cytotoxicity of ribonucleases, and may lead to a new class of drugs.
Insights
Ribonucleases, enzymes once overlooked, exhibit significant biological functions. Research into Onconase, a frog-derived ribonuclease, highlights their potential as novel cancer chemotherapeutics.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Ribonucleases were historically considered simple digestive enzymes.
- Emerging research reveals diverse and significant biological activities of ribonucleases.
- Onconase, a ribonuclease from the Northern leopard frog, is under investigation for cancer treatment.
Purpose of the Study:
- To explore the cytotoxic mechanisms of ribonucleases.
- To identify key factors contributing to ribonuclease-induced cell death.
- To evaluate the therapeutic potential of ribonucleases in cancer therapy.
Main Methods:
- Investigating the biological activities of specific ribonucleases.
- Analyzing the molecular mechanisms underlying ribonuclease cytotoxicity.
- Clinical evaluation of Onconase as a chemotherapeutic agent.
Main Results:
- Ribonucleases possess potent cytotoxic effects.
- Key molecular factors driving ribonuclease cytotoxicity have been identified.
- Onconase demonstrates promise in ongoing clinical trials for cancer treatment.
Conclusions:
- Ribonucleases have critical biological roles beyond digestion.
- Understanding ribonuclease cytotoxicity can pave the way for new cancer drugs.
- Onconase represents a potential new class of chemotherapeutic agents.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:47Ribozymes
The term ribozyme is used for RNA that can act as an enzyme. Ribozymes are mainly found in selected viruses, bacteria, plant organelles, and lower eukaryotes. Ribozymes were first discovered in 1982 when Tom Cech’s laboratory observed Group I introns acting as enzymes. This was shortly followed by the discovery of another ribozyme, Ribonulcease P, by Sid Altman’s laboratory. Both Cech and Altman received the Nobel Prize in chemistry in 1989 for their work on ribozymes.
Ribozymes can be...
Ribozymes can be...
02:47Ribozymes
The term ribozyme is used for RNA that can act as an enzyme. Ribozymes are mainly found in selected viruses, bacteria, plant organelles, and lower eukaryotes. Ribozymes were first discovered in 1982 when Tom Cech’s laboratory observed Group I introns acting as enzymes. This was shortly followed by the discovery of another ribozyme, Ribonulcease P, by Sid Altman’s laboratory. Both Cech and Altman received the Nobel Prize in chemistry in 1989 for their work on ribozymes.
Ribozymes can be...
Ribozymes can be...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...